A novel small-molecule inhibitor targeting the IL-6 receptor β subunit, glycoprotein 130

Soon Sun Hong, Jung Ho Choi, Sung Yoon Lee, Yeon Hwa Park, Kyung Yeon Park, Joo Young Lee, Juyoung Kim, Veeraswamy Gajulapati, Ja Il Goo, Sarbjit Singh, Kyeong Lee, Young Kook Kim, So Hee Im, Sung Hoon Ahn, Stefan Rose-John, Tae Hwe Heo, Yongseok Choi

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

IL-6 is a major causative factor of inflammatory disease. Although IL-6 and its signaling pathways are promising targets, orally available small-molecule drugs specific for IL-6 have not been developed. To discover IL-6 antagonists, we screened our in-house chemical library and identifiedLMT-28, a novel synthetic compound, as a candidate IL-6 blocker. The activity, mechanism of action, and direct molecular target of LMT-28 were investigated. A reporter gene assay showed that LMT-28 suppressed activation of STAT3 induced by IL-6, but not activation induced by leukemia inhibitory factor. In addition, LMT-28 downregulated IL-6-stimulated phosphorylation of STAT3, gp130, and JAK2 protein and substantially inhibited IL-6-dependent TF-1 cell proliferation. LMT-28 antagonized IL-6-induced TNF-α production in vivo. In pathologic models, oral administration of LMT-28 alleviated collagen-induced arthritis and acute pancreatitis in mice. Based on the observation of upstream IL-6 signal inhibition by LMT-28, we hypothesized IL-6, IL-6Rα, or gp130 to be putative molecular targets. We subsequently demonstrated direct interaction of LMT-28 with gp130 and specific reduction of IL-6/IL-6Rα complex binding to gp130 in the presence of LMT-28, which was measured by surface plasmon resonance analysis. Taken together, our data suggest that LMT-28 is a novel synthetic IL-6 inhibitor that functions through direct binding to gp130.

Original languageEnglish
Pages (from-to)237-245
Number of pages9
JournalJournal of Immunology
Volume195
Issue number1
DOIs
Publication statusPublished - 2015 Jul 1

Fingerprint

Interleukin-6 Receptors
Interleukin-6
Glycoproteins
Small Molecule Libraries
Leukemia Inhibitory Factor
LMT-28
Experimental Arthritis
Surface Plasmon Resonance
Reporter Genes
Pancreatitis
Oral Administration

ASJC Scopus subject areas

  • Immunology

Cite this

A novel small-molecule inhibitor targeting the IL-6 receptor β subunit, glycoprotein 130. / Hong, Soon Sun; Choi, Jung Ho; Lee, Sung Yoon; Park, Yeon Hwa; Park, Kyung Yeon; Lee, Joo Young; Kim, Juyoung; Gajulapati, Veeraswamy; Goo, Ja Il; Singh, Sarbjit; Lee, Kyeong; Kim, Young Kook; Im, So Hee; Ahn, Sung Hoon; Rose-John, Stefan; Heo, Tae Hwe; Choi, Yongseok.

In: Journal of Immunology, Vol. 195, No. 1, 01.07.2015, p. 237-245.

Research output: Contribution to journalArticle

Hong, SS, Choi, JH, Lee, SY, Park, YH, Park, KY, Lee, JY, Kim, J, Gajulapati, V, Goo, JI, Singh, S, Lee, K, Kim, YK, Im, SH, Ahn, SH, Rose-John, S, Heo, TH & Choi, Y 2015, 'A novel small-molecule inhibitor targeting the IL-6 receptor β subunit, glycoprotein 130', Journal of Immunology, vol. 195, no. 1, pp. 237-245. https://doi.org/10.4049/jimmunol.1402908
Hong, Soon Sun ; Choi, Jung Ho ; Lee, Sung Yoon ; Park, Yeon Hwa ; Park, Kyung Yeon ; Lee, Joo Young ; Kim, Juyoung ; Gajulapati, Veeraswamy ; Goo, Ja Il ; Singh, Sarbjit ; Lee, Kyeong ; Kim, Young Kook ; Im, So Hee ; Ahn, Sung Hoon ; Rose-John, Stefan ; Heo, Tae Hwe ; Choi, Yongseok. / A novel small-molecule inhibitor targeting the IL-6 receptor β subunit, glycoprotein 130. In: Journal of Immunology. 2015 ; Vol. 195, No. 1. pp. 237-245.
@article{4a35c42e9f554e43b11895c691792e67,
title = "A novel small-molecule inhibitor targeting the IL-6 receptor β subunit, glycoprotein 130",
abstract = "IL-6 is a major causative factor of inflammatory disease. Although IL-6 and its signaling pathways are promising targets, orally available small-molecule drugs specific for IL-6 have not been developed. To discover IL-6 antagonists, we screened our in-house chemical library and identifiedLMT-28, a novel synthetic compound, as a candidate IL-6 blocker. The activity, mechanism of action, and direct molecular target of LMT-28 were investigated. A reporter gene assay showed that LMT-28 suppressed activation of STAT3 induced by IL-6, but not activation induced by leukemia inhibitory factor. In addition, LMT-28 downregulated IL-6-stimulated phosphorylation of STAT3, gp130, and JAK2 protein and substantially inhibited IL-6-dependent TF-1 cell proliferation. LMT-28 antagonized IL-6-induced TNF-α production in vivo. In pathologic models, oral administration of LMT-28 alleviated collagen-induced arthritis and acute pancreatitis in mice. Based on the observation of upstream IL-6 signal inhibition by LMT-28, we hypothesized IL-6, IL-6Rα, or gp130 to be putative molecular targets. We subsequently demonstrated direct interaction of LMT-28 with gp130 and specific reduction of IL-6/IL-6Rα complex binding to gp130 in the presence of LMT-28, which was measured by surface plasmon resonance analysis. Taken together, our data suggest that LMT-28 is a novel synthetic IL-6 inhibitor that functions through direct binding to gp130.",
author = "Hong, {Soon Sun} and Choi, {Jung Ho} and Lee, {Sung Yoon} and Park, {Yeon Hwa} and Park, {Kyung Yeon} and Lee, {Joo Young} and Juyoung Kim and Veeraswamy Gajulapati and Goo, {Ja Il} and Sarbjit Singh and Kyeong Lee and Kim, {Young Kook} and Im, {So Hee} and Ahn, {Sung Hoon} and Stefan Rose-John and Heo, {Tae Hwe} and Yongseok Choi",
year = "2015",
month = "7",
day = "1",
doi = "10.4049/jimmunol.1402908",
language = "English",
volume = "195",
pages = "237--245",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "1",

}

TY - JOUR

T1 - A novel small-molecule inhibitor targeting the IL-6 receptor β subunit, glycoprotein 130

AU - Hong, Soon Sun

AU - Choi, Jung Ho

AU - Lee, Sung Yoon

AU - Park, Yeon Hwa

AU - Park, Kyung Yeon

AU - Lee, Joo Young

AU - Kim, Juyoung

AU - Gajulapati, Veeraswamy

AU - Goo, Ja Il

AU - Singh, Sarbjit

AU - Lee, Kyeong

AU - Kim, Young Kook

AU - Im, So Hee

AU - Ahn, Sung Hoon

AU - Rose-John, Stefan

AU - Heo, Tae Hwe

AU - Choi, Yongseok

PY - 2015/7/1

Y1 - 2015/7/1

N2 - IL-6 is a major causative factor of inflammatory disease. Although IL-6 and its signaling pathways are promising targets, orally available small-molecule drugs specific for IL-6 have not been developed. To discover IL-6 antagonists, we screened our in-house chemical library and identifiedLMT-28, a novel synthetic compound, as a candidate IL-6 blocker. The activity, mechanism of action, and direct molecular target of LMT-28 were investigated. A reporter gene assay showed that LMT-28 suppressed activation of STAT3 induced by IL-6, but not activation induced by leukemia inhibitory factor. In addition, LMT-28 downregulated IL-6-stimulated phosphorylation of STAT3, gp130, and JAK2 protein and substantially inhibited IL-6-dependent TF-1 cell proliferation. LMT-28 antagonized IL-6-induced TNF-α production in vivo. In pathologic models, oral administration of LMT-28 alleviated collagen-induced arthritis and acute pancreatitis in mice. Based on the observation of upstream IL-6 signal inhibition by LMT-28, we hypothesized IL-6, IL-6Rα, or gp130 to be putative molecular targets. We subsequently demonstrated direct interaction of LMT-28 with gp130 and specific reduction of IL-6/IL-6Rα complex binding to gp130 in the presence of LMT-28, which was measured by surface plasmon resonance analysis. Taken together, our data suggest that LMT-28 is a novel synthetic IL-6 inhibitor that functions through direct binding to gp130.

AB - IL-6 is a major causative factor of inflammatory disease. Although IL-6 and its signaling pathways are promising targets, orally available small-molecule drugs specific for IL-6 have not been developed. To discover IL-6 antagonists, we screened our in-house chemical library and identifiedLMT-28, a novel synthetic compound, as a candidate IL-6 blocker. The activity, mechanism of action, and direct molecular target of LMT-28 were investigated. A reporter gene assay showed that LMT-28 suppressed activation of STAT3 induced by IL-6, but not activation induced by leukemia inhibitory factor. In addition, LMT-28 downregulated IL-6-stimulated phosphorylation of STAT3, gp130, and JAK2 protein and substantially inhibited IL-6-dependent TF-1 cell proliferation. LMT-28 antagonized IL-6-induced TNF-α production in vivo. In pathologic models, oral administration of LMT-28 alleviated collagen-induced arthritis and acute pancreatitis in mice. Based on the observation of upstream IL-6 signal inhibition by LMT-28, we hypothesized IL-6, IL-6Rα, or gp130 to be putative molecular targets. We subsequently demonstrated direct interaction of LMT-28 with gp130 and specific reduction of IL-6/IL-6Rα complex binding to gp130 in the presence of LMT-28, which was measured by surface plasmon resonance analysis. Taken together, our data suggest that LMT-28 is a novel synthetic IL-6 inhibitor that functions through direct binding to gp130.

UR - http://www.scopus.com/inward/record.url?scp=84932163442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84932163442&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1402908

DO - 10.4049/jimmunol.1402908

M3 - Article

C2 - 26026064

AN - SCOPUS:84932163442

VL - 195

SP - 237

EP - 245

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 1

ER -